Caluire Et Cuire

Researchers are investigating metastatic colorectal cancer mCRC patients who have a specific genetic change called the BRAFV600E mutation. This rare subtype of mCRC often shows poor response to current treatments and has a generally poor outlook. The study aims to collect detailed clinical data and biological samples to better understand this condition, including how patients respond to treatments and what factors predict their survival. It focuses on real-world treatment outcomes and biological markers that might influence therapy choices and resistance. Participants will provide blood samples at multiple times during their treatment, including before and during the first three treatment cycles, at 3 and 6 months after starting each treatment line, and when disease progression occurs following certain therapies. The study gathers up to 390 mL of blood per participant over time to analyze circulating tumor DNA and immune environment factors. This observational approach will help researchers identify biomarkers related to treatment response and disease progression. During the study, participants clinical progress and survival will be tracked for up to five years. Researchers will review overall survival from diagnosis to death and assess how prognostic markers relate to progression-free survival and response to treatments. The study involves collecting tumor tissue samples and blood tests, along with routine follow-up visits. All data collected will contribute to understanding BRAFV600E mCRC and improving future treatment strategies.

Psoriatic arthritis PsA is a long-lasting inflammatory condition affecting joints and skin in people with psoriasis. This trial evaluates how well the drug zasocitinib TAK-279 works in adults with active PsA, focusing on participants past experiences with certain treatments. The study is a phase 3 clinical trial designed to assess treatment effectiveness and safety. Participants will be randomly assigned to one of three groups one receiving zasocitinib Dose A tablets once daily for up to 52 weeks, another receiving zasocitinib Dose B tablets once daily for up to 52 weeks, and a third group receiving a placebo once daily for 16 weeks followed by either Dose A or Dose B of zasocitinib once daily through week 52. This design allows comparison of doses and placebo effects during the early treatment period. During the study, participants will undergo regular assessments including joint counts and skin evaluations to monitor disease activity and response to treatment. Researchers will measure the percentage of participants achieving specific response criteria such as the American College of Rheumatology 20 ACR20 response at week 16. Safety and other health outcomes like fatigue, physical function, and quality of life will also be tracked. Total participation can last up to 60 weeks, including treatment and follow-up periods.

Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.

Rheumatoid arthritis RA is a common inflammatory joint disease. Researchers are studying an individualized strategy to reduce the dose of adalimumab, a biological drug, in patients who have achieved remission. The study aims to find the best adalimumab blood concentration to maintain before tapering treatment, as current guidelines for stepping down medication are unclear and flares may occur during tapering. Participants receive adalimumab injections combined with methotrexate and will be randomly assigned to one of three groups a single-arm group following a clinical tapering strategy based on disease activity every three months, a maintenance group continuing the same adalimumab regimen, or an optimized tapering group where the timing of dose spacing depends on adalimumab trough blood levels. The tapering process and group assignment are randomized over 12 months. During the study, participants will be assessed every three months using disease activity scores to monitor flares. Researchers will track flare-ups over 15 months as the primary outcome, with infections as a secondary outcome. Participants medication doses and health status will be regularly evaluated to guide tapering and ensure safety throughout the study period.

Researchers are studying how to adjust the dose of fluoropyrimidine chemotherapy based on uracilemia levels in patients with DPD deficiency who have gastrointestinal cancers. This phase II multicenter trial aims to find the best dose reduction strategy to reduce side effects while treating digestive cancers. The main question is which dose reduction is needed for patients with this enzyme deficiency. Participants will receive chemotherapy with doses adjusted according to their uracilemia level. Patients with low uracilemia <16 ngmL will get the full dose, while those with higher levels will receive varying dose reductions or random assignments between 25% and 50% reductions depending on their uracilemia range. Treatments include the FOLFOX or CAPOX chemotherapy regimens, given in cycles every 2 to 3 weeks. During the study, participants will visit the clinic every 2 to 3 weeks for checkups and tests to monitor side effects and treatment response. Researchers will measure the occurrence of serious blood and gastrointestinal toxicities after two treatment cycles and track dose adjustments, toxicity, and survival outcomes over several months and years. The study involves close monitoring of health and treatment effects for up to three years, depending on cancer stage.

Researchers are evaluating sonelokimab in adults with active psoriatic arthritis who have not had adequate results or could not tolerate prior anti-tumor necrosis factor TNF alpha therapy. This Phase 3, multicenter, randomized, double-blind study compares the safety and effectiveness of two doses of sonelokimab against placebo and an active reference treatment called risankizumab. Participants are randomly assigned to one of four groups one receiving sonelokimab dose 1, another receiving sonelokimab dose 2, one receiving placebo, and one receiving risankizumab. Those in the sonelokimab groups receive four initial subcutaneous doses as induction, then maintenance doses every four weeks starting at Week 8. The placebo and risankizumab groups receive their respective treatments subcutaneously according to the study protocol. During the study, participants will undergo assessments of joint tenderness and swelling, skin psoriasis activity, physical function, and quality of life at Week 16. Researchers will monitor response rates based on improvement criteria such as the American College of Rheumatology 50% improvement ACR50. Safety and tolerability will also be followed throughout the trial, which is expected to complete by January 2027.

Squamous cell carcinoma of the anus is a rare but increasingly common cancer, often linked to human papillomavirus HPV. For early-stage tumors, combined radiotherapy and chemotherapy with 5FU and mitomycin-C provide good outcomes, but advanced tumors have a poor prognosis with a high relapse rate. Researchers are studying a new approach combining induction chemotherapy with docetaxel, cisplatin, and 5FU mDCF followed by standard chemoradiotherapy to improve treatment results for locally advanced anal cancer T3-4 or N1. This is a randomized phase 3 trial comparing this new strategy to the current standard treatment. The study includes two groups one receives the usual chemoradiotherapy, which involves 33 radiotherapy sessions over 6.5 weeks combined with mitomycin-C and capecitabine chemotherapy taken on radiotherapy days. The other group starts with 4 cycles of mDCF chemotherapy given every two weeks before receiving the same chemoradiotherapy as the control group. Radiotherapy uses intensity-modulated external irradiation with a targeted boost to the tumor and involved lymph nodes. Participants will be followed after treatment with check-ups at 8 weeks, then every 4 months for two years, and every 6 months in the third year. Follow-up includes clinical exams and imaging scans CT and MRI. The main measure of success is disease-related event-free survival two years after treatment. Other outcomes include overall survival, colostomy-free survival, treatment side effects, tumor response, and quality of life. The total study duration for each participant may extend over several years including this follow-up period.

Researchers are evaluating two methods of managing blood flow during off-pump coronary artery bypass graft CABG surgery in adults with coronary artery disease. The study compares postural mobilization, specifically passive leg raising, with the use of noradrenaline alone. The goal is to determine how often noradrenaline is needed when using postural mobilization and to compare surgical outcomes and complications between the two groups. The study involves two groups one where patients receive postural mobilization by raising their legs to about a 45 angle before any noradrenaline is given, and a control group where only noradrenaline is used to manage blood flow without leg raising. Postural mobilization is applied to help stabilize hemodynamics, and noradrenaline is used if needed. This intervention occurs during the heart surgery itself. Participants will be monitored during surgery and followed for 30 days afterward to assess how hemodynamics were managed, the rate of revascularization, and any post-operative complications. Researchers will measure the use of noradrenaline from the start to the end of surgery and observe patient outcomes during the follow-up period. The total participation includes the surgery day and 30 days post-surgery monitoring.

Alzheimers disease and related disorders cause significant challenges such as memory loss, reduced ability to perform daily activities, and behavioral problems. Without current cures, identifying factors that predict how the disease progresses is important for public health. This study aims to create a database of medical records from about 1000 patients with memory impairment to examine these predictive factors over time. The follow-up period for each patient is planned to last 3 years. Participants will have their level of functional autonomy assessed every 6 to 12 months through phone calls using tools like the Lawton Instrumental Activities of Daily Living score IADL and the Disability Assessment of Dementia score DAD-6. These assessments focus on how well patients manage daily tasks and their level of disability related to dementia. The study is observational with no masking or placebo control. During the study, patients will be monitored regularly for changes in their ability to function and cognitive status. The main outcome measured is the change in functional autonomy over 3 years, with cognitive function also tracked. Data collection relies on medical visits at a Memory Clinic and phone assessments, enabling researchers to study disease progression and related factors. The total participation duration for each patient is 3 years.

Alzheimers disease and related disorders ADRD are disabling conditions characterized by cognitive decline, loss of independence, and behavioral changes. Without a current cure, this study aims to identify factors that predict how patients ability to function changes over time. The research involves building a regional database of medical records from patients in the Auvergne Rhone-Alpes region of France to better understand disease progression. Participants are patients with memory complaints or neurocognitive disorders who undergo medical examinations at memory centers. The study follows about 5400 patients over a maximum of 10 years, with evaluations every 6 to 12 months. These assessments measure functional autonomy and include tests like IADL, DAD6, New AGGIR, NPI, and mini-Zarit to evaluate independence, behavior, and caregiver burden. During the study, patients receive standard medical care and extensive evaluations at regular intervals. Researchers track changes in each patients functional autonomy over time as the main outcome. The study began in September 2020 and will continue until March 2032, allowing long-term observation of disease progression and its impact on daily living.